Skip to content

Author

Lauren Hong

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Programmable protein degraders enable selective knockdown of pathogenic β-catenin subpopulations in vitro and in vivo

Aberrant activation of Wnt signaling results in unregulated accumulation of cytosolic β-catenin, which subsequently enters the nucleus and promotes transcription of genes that contribute to cellular proliferation and malignancy. Here, we sought to eliminate pathogenic β-catenin from the cytosol using designer ubiquibodies (uAbs), chimeric proteins composed of an E3 ubiquitin ligase and a target-binding domain that redirect intracellular proteins to the proteasome for degradation. To accelerate uAb development, we leveraged a protein language model–driven algorithm called SaLT&PepPr to computationally design “guide” peptides with affinity for β-catenin, which were subsequently fused to the catalytic domain of a human E3 called carboxyl terminus of Hsp70-interacting protein. Expression of the resulting peptide-guided uAbs in colorectal cancer cells led to the identification of several designs that greatly reduced the abnormally stable pool of free β-catenin in the cytosol and nucleus while preserving the normal membrane–associated subpopulation. This selective knockdown of pathogenic β-catenin suppressed Wnt/β-catenin signaling and impaired tumor cell survival and proliferation. Furthermore, one of the best degraders selectively decreased cytosolic but not membrane-associated β-catenin levels in livers of BALB/c mice following delivery as a lipid nanoparticle–encapsulated mRNA. Collectively, these findings reveal the unique ability of uAbs to selectively deplete abnormal proteins in vitro and in vivo and open the door to peptide-programmable biologic modulators of other disease-causing proteins.

Tianzheng Ye, A. Alamgir, C. Robertus et al. · 0 citations
Open access Aug 2026

A Mammalian High-Throughput Screen for AI-Designed Peptide-Guided Protein Degraders

Targeted protein degradation (TPD) offers a route to eliminate disease-driving proteins that remain inaccessible to conventional inhibitors. However, degrader discovery remains low-throughput, labor-intensive, and dependent on randomized libraries or non-human display systems, limiting functional selection in mammalian cells. Here, we present a high-throughput, human cell-based platform for screening peptide-guided ubiquibodies (uAbs). These genetically encodable, doxycycline-inducible degraders fuse peptide guides generated by protein language models to the CHIPΔTPR E3 ligase domain, creating a modular, CRISPR-like system for programmable TPD. For each target, we introduce a pooled uAb library into the corresponding fluorescent reporter cell line, isolate cells with reduced target abundance by FACS, and recover enriched peptide guides by sequencing. For β-catenin, enriched uAbs reduced endogenous β-catenin abundance and Wnt signaling in DLD1 cells. GFAP-directed uAbs reduced endogenous GFAP abundance and cell viability in U251 glioblastoma cells, while EWS::FLI1-directed uAbs reduced fusion oncoprotein abundance, suppressed EWSAT1 expression, and increased apoptosis in Ewing sarcoma models. Finally, a screen using endogenously tagged GATA2 further identified uAbs that reduced GATA2 under native genomic regulation. Overall, our platform connects generative peptide design to functional mammalian selection and establishes a scalable strategy for CRISPR-like proteome perturbation.

Lin Zhao, Anuoluwapo A. Mattix, Aastha Pal et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.